Literature DB >> 35560164

Conversion of Classical and 11-Oxygenated Androgens by Insulin-Induced AKR1C3 in a Model of Human PCOS Adipocytes.

Ryan D Paulukinas1,2, Clementina A Mesaros1,2, Trevor M Penning1,2.   

Abstract

Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women. A common symptom of PCOS is hyperandrogenism (AE); however, the source of these androgens is uncertain. Aldo-keto reductase family 1 member C3 (AKR1C3) catalyzes the formation of testosterone (T) and 5α-dihydrotestosterone (DHT) in peripheral tissues, which activate the androgen receptor (AR). AKR1C3 is induced by insulin in adipocytes and may be central in driving the AE in PCOS. We elucidated the conversion of both classical and 11-oxygenated androgens to potent androgens in a model of PCOS adipocytes. Using high-performance liquid chromatography (HPLC) discontinuous kinetic assays to measure product formation by recombinant AKR1C3, we found that the conversion of 11-keto-Δ4-androstene-3,17-dione (11K-4AD) to 11-ketotestosterone (11K-T) and 11-keto-5α-androstane-3,17-dione (11K-5AD) to 11-keto-5α-dihydrotestosterone (11K-DHT) were superior to the formation of T and DHT. We utilized a stable isotope dilution liquid chromatography high resolution mass spectrometric (SID-LC-HRMS) assay for the quantification of both classical and 11-oxygenated androgens in differentiated Simpson-Golabi-Behmel syndrome adipocytes in which AKR1C3 was induced by insulin. Adipocytes were treated with adrenal derived 11β-hydroxy-Δ4-androstene-3,17-dione (11β-OH-4AD), 11K-4AD, or Δ4-androstene-3,17-dione (4AD). The conversion of 11β-OH-4AD and 11K-4AD to 11K-T required AKR1C3. We also found that once 11K-T is formed, it is inactivated to 11β-hydroxy-testosterone (11β-OH-T) by 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1). Our data reveal a unique role for HSD11B1 in protecting the AR from AE. We conclude that the 11-oxygenated androgens formed in adipocytes may contribute to the hyperandrogenic profile of PCOS women and that AKR1C3 is a potential therapeutic target to mitigate the AE of PCOS.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Simpson-Golabi-Behmel syndrome; androgen excess; hydroxysteroid dehydrogenase; insulin resistance; mass spectrometry

Mesh:

Substances:

Year:  2022        PMID: 35560164      PMCID: PMC9162389          DOI: 10.1210/endocr/bqac068

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   5.051


  46 in total

1.  Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).

Authors:  Adegoke O Adeniji; Barry M Twenter; Michael C Byrns; Yi Jin; Jeffrey D Winkler; Trevor M Penning
Journal:  Bioorg Med Chem Lett       Date:  2011-01-07       Impact factor: 2.823

Review 2.  The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies.

Authors:  Ilana J Halperin; Shoba Sujana Kumar; Donna F Stroup; Sheila E Laredo
Journal:  Hum Reprod       Date:  2010-11-08       Impact factor: 6.918

3.  Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry.

Authors:  Tianzhu Zang; Daniel Tamae; Clementina Mesaros; Qingqing Wang; Meng Huang; Ian A Blair; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2016-08-12       Impact factor: 4.292

4.  11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?

Authors:  Karl-Heinz Storbeck; Liezl M Bloem; Donita Africander; Lindie Schloms; Pieter Swart; Amanda C Swart
Journal:  Mol Cell Endocrinol       Date:  2013-07-13       Impact factor: 4.102

5.  Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.

Authors:  Hsueh-Kung Lin; Stephan Steckelbroeck; Kar-Ming Fung; Amy N Jones; Trevor M Penning
Journal:  Steroids       Date:  2004-12       Impact factor: 2.668

6.  Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.

Authors:  L Falsetti; E Pasinetti
Journal:  Acta Obstet Gynecol Scand       Date:  1995-01       Impact factor: 3.636

7.  11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome.

Authors:  Tomoko Yoshida; Toshiya Matsuzaki; Mami Miyado; Kazuki Saito; Takeshi Iwasa; Yoichi Matsubara; Tsutomu Ogata; Minoru Irahara; Maki Fukami
Journal:  Endocr J       Date:  2018-07-14       Impact factor: 2.349

8.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.

Authors:  Neil F Goodman; Rhoda H Cobin; Walter Futterweit; Jennifer S Glueck; Richard S Legro; Enrico Carmina
Journal:  Endocr Pract       Date:  2015-11       Impact factor: 3.443

9.  Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.

Authors:  Tjeerd Barf; Jerk Vallgårda; Rikard Emond; Charlotta Häggström; Guido Kurz; Alf Nygren; Vivienne Larwood; Erifili Mosialou; Kent Axelsson; Rolf Olsson; Lars Engblom; Naimie Edling; Yuko Rönquist-Nii; Birgitta Ohman; Peteris Alberts; Lars Abrahmsén
Journal:  J Med Chem       Date:  2002-08-29       Impact factor: 7.446

10.  11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome.

Authors:  Michael W O'Reilly; Punith Kempegowda; Carl Jenkinson; Angela E Taylor; Jonathan L Quanson; Karl-Heinz Storbeck; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2017-03-01       Impact factor: 5.958

View more
  1 in total

1.  Conversion of Classical and 11-Oxygenated Androgens by Insulin-Induced AKR1C3 in a Model of Human PCOS Adipocytes.

Authors:  Ryan D Paulukinas; Clementina A Mesaros; Trevor M Penning
Journal:  Endocrinology       Date:  2022-07-01       Impact factor: 5.051

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.